Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCIHirotoshi Watanabe, Takenori Domei, Takeshi Morimoto et al.|JAMA|2019Cited by 830
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary InterventionKenichi Tsujita, Hisao Ogawa, Naritsugu Sakaino et al.|Journal of the American College of Cardiology|2015Cited by 449
Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary SyndromeHirotoshi Watanabe, Motoaki Higuchi, Takeshi Morimoto et al.|JAMA Cardiology|2022Cited by 296
Expression of Angiotensin-Converting Enzyme in Remaining Viable Myocytes of Human Ventricles After Myocardial InfarctionSeiji Hokimoto, Eishichi Miyamoto, Hirofumi Yasue et al.|Circulation|1996Cited by 105
One-year outcome of a prospective trial stopping dual antiplatelet therapy at 3 months after everolimus-eluting cobalt-chromium stent implantation: ShortT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent (STOPDAPT) trialMasahiro Natsuaki, Takeshi Kimura, Takeshi Morimoto et al.|Cardiovascular Intervention and Therapeutics|2015Cited by 76